174 related articles for article (PubMed ID: 33338470)
1. Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes.
Popovic MM; Nichani P; Muni RH; Mireskandari K; Tehrani NN; Kertes PJ
Surv Ophthalmol; 2021; 66(4):572-584. PubMed ID: 33338470
[TBL] [Abstract][Full Text] [Related]
2. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.
Ortiz-Seller A; Martorell P; Barranco H; Pascual-Camps I; Morcillo E; Ortiz JL
Surv Ophthalmol; 2024; 69(4):585-605. PubMed ID: 38432359
[TBL] [Abstract][Full Text] [Related]
3. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
Chang E; Josan AS; Purohit R; Patel CK; Xue K
Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
5. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
[TBL] [Abstract][Full Text] [Related]
6. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A
Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
[TBL] [Abstract][Full Text] [Related]
8. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis.
Kong Q; Ming WK; Mi XS
BMJ Open; 2021 Feb; 11(2):e042384. PubMed ID: 33568373
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety.
Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
Br J Ophthalmol; 2019 Sep; 103(9):1332-1336. PubMed ID: 30514709
[TBL] [Abstract][Full Text] [Related]
11. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity.
Hoppe C; Holt DG; Arnold BF; Thinda S; Padmanabhan SP; Oatts JT
J AAPOS; 2022 Dec; 26(6):305.e1-305.e6. PubMed ID: 36265750
[TBL] [Abstract][Full Text] [Related]
12. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
13. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
Tan QQ; Christiansen SP; Wang J
PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO
Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033
[TBL] [Abstract][Full Text] [Related]
15. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
Kang HG; Kim TY; Han J; Han SH
Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
19. OUTCOMES OF NONCONFLUENT DIODE LASER PANRETINAL PHOTOCOAGULATION FOR AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB.
Mammo DA; Rubino SM; Quiram PA
Retina; 2021 Apr; 41(4):706-710. PubMed ID: 32796444
[TBL] [Abstract][Full Text] [Related]
20. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]